{"id":9370,"date":"2026-02-18T10:51:36","date_gmt":"2026-02-18T09:51:36","guid":{"rendered":"https:\/\/hemerion.com\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/"},"modified":"2026-02-18T11:00:14","modified_gmt":"2026-02-18T10:00:14","slug":"retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome","status":"publish","type":"post","link":"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/","title":{"rendered":"Retour positif de la FDA sur la strat\u00e9gie clinique de Pentalafen\u00ae \/ Heliance\u00ae dans le traitement du cancer du cerveau, le glioblastome"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>La Food &amp; Drug Administration (FDA) a rendu un avis positif sur la strat\u00e9gie clinique d\u00e9velopp\u00e9e par Hemerion pour sa th\u00e9rapie Pentalafen\u00ae \/ Heliance\u00ae suite \u00e0 un Type C Meeting tenu en novembre 2025. L\u2019administration sanitaire am\u00e9ricaine valide notamment la possibilit\u00e9 d\u2019une proc\u00e9dure acc\u00e9l\u00e9r\u00e9e d\u2019autorisation de mise sur le march\u00e9 (Accelerated Approval) et confirme la pertinence de la strat\u00e9gie clinique et r\u00e9glementaire pour la technologie Pentalafen\u00ae \/ Heliance\u00ae dans le traitement des glioblastomes nouvellement diagnostiqu\u00e9s aux USA. <\/strong><\/p>\n\n<p class=\"wp-block-paragraph\">Alors que les \u00e9tudes cliniques de phase 1 \/ 2 pour cette th\u00e9rapie touchent \u00e0 leur fin, Hemerion a re\u00e7u en d\u00e9cembre 2025 un retour tr\u00e8s positif de la FDA sur la pertinence de sa strat\u00e9gie clinique \u00e0 venir, suite \u00e0 un \u201cType C Meeting\u201d organis\u00e9 en novembre 2025.<\/p>\n\n<p class=\"wp-block-paragraph\">Ce type de r\u00e9union formelle permet de discuter de points pr\u00e9cis avec la FDA et d\u2019obtenir des retours clairs de l\u2019agence : une \u00e9tape essentielle, qui s\u00e9curise le d\u00e9veloppement clinique et la strat\u00e9gie r\u00e9glementaire mis en place par Hemerion.<\/p>\n\n<h2 class=\"gb-headline gb-headline-06cdf13f gb-headline-text\">La FDA confirme son accord de principe sur une proc\u00e9dure d\u2019Accelerated Approval<\/h2>\n\n<p class=\"wp-block-paragraph\">Apr\u00e8s cet \u00e9change, la FDA a confirm\u00e9 l\u2019\u00e9ligibilit\u00e9 de la th\u00e9rapie Pentalafen \/ Heliance \u00e0 une proc\u00e9dure d\u2019Accelerated Approval. Cette proc\u00e9dure permet \u00e0 des th\u00e9rapies destin\u00e9es \u00e0 des pathologies graves en impasse th\u00e9rapeutique d\u2019obtenir une autorisation de mise sur le march\u00e9 plus rapide, sur la base d\u2019un crit\u00e8re clinique de substitution (surrogate endpoint). <\/p>\n\n<p class=\"wp-block-paragraph\">Cette proc\u00e9dure permettrait \u00e0 Hemerion de b\u00e9n\u00e9ficier d\u2019une autorisation conditionnelle de mise sur le march\u00e9 \u00e0 un stade interm\u00e9diaire, tout en continuant le d\u00e9veloppement clinique, pour obtenir l\u2019autorisation d\u00e9finitive. Elle ouvrirait ainsi la possibilit\u00e9 d\u2019une mise sur le march\u00e9 de la th\u00e9rapie Pentalafen \/ Heliance d\u00e8s 2030 sur le march\u00e9 am\u00e9ricain : un v\u00e9ritable coup d\u2019acc\u00e9l\u00e9rateur pour Hemerion.<\/p>\n\n<h2 class=\"gb-headline gb-headline-07489ad6 gb-headline-text\">Une strat\u00e9gie clinique globale approuv\u00e9e<\/h2>\n\n<p class=\"wp-block-paragraph\">La FDA a aussi valid\u00e9 l\u2019approche clinique et statistique globale de l\u2019essai pour une autorisation d\u00e9finitive, qui serait accord\u00e9e dans un deuxi\u00e8me temps.<\/p>\n\n<p class=\"wp-block-paragraph\">Les \u00e9changes tr\u00e8s fructueux men\u00e9s avec la FDA ont aussi permis aux \u00e9quipes Hemerion de compl\u00e9ter et d\u2019enrichir le design de l\u2019essai, pour renforcer sa pr\u00e9cision et sa pertinence.<\/p>\n\n<h2 class=\"gb-headline gb-headline-c69de911 gb-headline-text\">Pentalafen\u00ae : double indication valid\u00e9e pour la mol\u00e9cule d\u00e9velopp\u00e9e par Hemerion<\/h2>\n\n<p class=\"wp-block-paragraph\">The FDA also confirmed the potential for Pentalafen\u00ae to cover two complementary indications: fluorescence-guided visualization of tumor cells to optimize surgery, and photodynamic therapy (PDT) to treat residual tumor cells.<\/p>\n\n<p class=\"wp-block-paragraph\">La FDA a \u00e9galement confirm\u00e9 son accord sur la possibilit\u00e9 pour le Pentalafen\u00ae de couvrir deux indications :<br\/>&#8211; Visualisation des cellules tumorales par fluorescence pour optimiser la chirurgie<br\/>&#8211; Traitement par phototh\u00e9rapie dynamique des cellules tumorales r\u00e9siduelles<br\/>Cette double indication donne au Pentalafen@ une position unique et tr\u00e8s prometteuse sur le march\u00e9 am\u00e9ricain de la chirurgie.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La Food &amp; Drug Administration (FDA) a rendu un avis positif sur la strat\u00e9gie clinique d\u00e9velopp\u00e9e par Hemerion pour sa th\u00e9rapie Pentalafen\u00ae \/ Heliance\u00ae suite \u00e0 un Type C Meeting tenu en novembre 2025. L\u2019administration sanitaire am\u00e9ricaine valide notamment la possibilit\u00e9 d\u2019une proc\u00e9dure acc\u00e9l\u00e9r\u00e9e d\u2019autorisation de mise sur le march\u00e9 (Accelerated Approval) et confirme la &#8230; <\/p>\n<p class=\"read-more-container\"><a title=\"Retour positif de la FDA sur la strat\u00e9gie clinique de Pentalafen\u00ae \/ Heliance\u00ae dans le traitement du cancer du cerveau, le glioblastome\" class=\"read-more button\" href=\"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/#more-9370\" aria-label=\"En savoir plus sur Retour positif de la FDA sur la strat\u00e9gie clinique de Pentalafen\u00ae \/ Heliance\u00ae dans le traitement du cancer du cerveau, le glioblastome\">Lire plus<\/a><\/p>\n","protected":false},"author":207845438,"featured_media":9369,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_jet_sm_ready_style":"","_jet_sm_style":"","_jet_sm_controls_values":"","_jet_sm_fonts_collection":"","_jet_sm_fonts_links":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[6342],"tags":[],"class_list":["post-9370","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Retour positif de la FDA sur la strat\u00e9gie clinique de Pentalafen\u00ae \/ Heliance\u00ae dans le traitement du cancer du cerveau, le glioblastome - Hemerion<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retour positif de la FDA sur la strat\u00e9gie clinique de Pentalafen\u00ae \/ Heliance\u00ae dans le traitement du cancer du cerveau, le glioblastome - Hemerion\" \/>\n<meta property=\"og:description\" content=\"La Food &amp; Drug Administration (FDA) a rendu un avis positif sur la strat\u00e9gie clinique d\u00e9velopp\u00e9e par Hemerion pour sa th\u00e9rapie Pentalafen\u00ae \/ Heliance\u00ae suite \u00e0 un Type C Meeting tenu en novembre 2025. L\u2019administration sanitaire am\u00e9ricaine valide notamment la possibilit\u00e9 d\u2019une proc\u00e9dure acc\u00e9l\u00e9r\u00e9e d\u2019autorisation de mise sur le march\u00e9 (Accelerated Approval) et confirme la ... Lire plus\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/\" \/>\n<meta property=\"og:site_name\" content=\"Hemerion\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-18T09:51:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-18T10:00:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/hemerion-treatment.jpg?fit=2000%2C1328&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"2000\" \/>\n\t<meta property=\"og:image:height\" content=\"1328\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Simon Delmotte\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HemerionTx\" \/>\n<meta name=\"twitter:site\" content=\"@HemerionTx\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Simon Delmotte\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\\\/\"},\"author\":{\"name\":\"Simon Delmotte\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#\\\/schema\\\/person\\\/ec5b45c7f7f52200ee5073ce247a86c7\"},\"headline\":\"Retour positif de la FDA sur la strat\u00e9gie clinique de Pentalafen\u00ae \\\/ Heliance\u00ae dans le traitement du cancer du cerveau, le glioblastome\",\"datePublished\":\"2026-02-18T09:51:36+00:00\",\"dateModified\":\"2026-02-18T10:00:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\\\/\"},\"wordCount\":518,\"publisher\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/hemerion.com\\\/wp-content\\\/uploads\\\/hemerion-treatment.jpg?fit=2000%2C1328&ssl=1\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\\\/\",\"url\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\\\/\",\"name\":\"Retour positif de la FDA sur la strat\u00e9gie clinique de Pentalafen\u00ae \\\/ Heliance\u00ae dans le traitement du cancer du cerveau, le glioblastome - Hemerion\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/hemerion.com\\\/wp-content\\\/uploads\\\/hemerion-treatment.jpg?fit=2000%2C1328&ssl=1\",\"datePublished\":\"2026-02-18T09:51:36+00:00\",\"dateModified\":\"2026-02-18T10:00:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/hemerion.com\\\/fr\\\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/hemerion.com\\\/wp-content\\\/uploads\\\/hemerion-treatment.jpg?fit=2000%2C1328&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/hemerion.com\\\/wp-content\\\/uploads\\\/hemerion-treatment.jpg?fit=2000%2C1328&ssl=1\",\"width\":2000,\"height\":1328,\"caption\":\"Application de la solution Hemerion au bloc op\u00e9ratoire\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Retour positif de la FDA sur la strat\u00e9gie clinique de Pentalafen\u00ae \\\/ Heliance\u00ae dans le traitement du cancer du cerveau, le glioblastome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/\",\"name\":\"Hemerion\",\"description\":\"Advancing cancer therapies at the speed of light\",\"publisher\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#organization\",\"name\":\"Hemerion\",\"url\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/hemerion.com\\\/wp-content\\\/uploads\\\/hemerion-logo.png?fit=1581%2C460&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/hemerion.com\\\/wp-content\\\/uploads\\\/hemerion-logo.png?fit=1581%2C460&ssl=1\",\"width\":1581,\"height\":460,\"caption\":\"Hemerion\"},\"image\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/HemerionTx\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hemerion-therapeutics\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCWwcUj-aSdo32OYwN5vjf8Q\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#\\\/schema\\\/person\\\/ec5b45c7f7f52200ee5073ce247a86c7\",\"name\":\"Simon Delmotte\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2f742e1ce87613e0ccca0877b0360f87beea918ba8e5efe3717e2c5285bfdc28?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2f742e1ce87613e0ccca0877b0360f87beea918ba8e5efe3717e2c5285bfdc28?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/2f742e1ce87613e0ccca0877b0360f87beea918ba8e5efe3717e2c5285bfdc28?s=96&d=identicon&r=g\",\"caption\":\"Simon Delmotte\"},\"url\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/author\\\/simondelmotte\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Retour positif de la FDA sur la strat\u00e9gie clinique de Pentalafen\u00ae \/ Heliance\u00ae dans le traitement du cancer du cerveau, le glioblastome - Hemerion","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/","og_locale":"fr_FR","og_type":"article","og_title":"Retour positif de la FDA sur la strat\u00e9gie clinique de Pentalafen\u00ae \/ Heliance\u00ae dans le traitement du cancer du cerveau, le glioblastome - Hemerion","og_description":"La Food &amp; Drug Administration (FDA) a rendu un avis positif sur la strat\u00e9gie clinique d\u00e9velopp\u00e9e par Hemerion pour sa th\u00e9rapie Pentalafen\u00ae \/ Heliance\u00ae suite \u00e0 un Type C Meeting tenu en novembre 2025. L\u2019administration sanitaire am\u00e9ricaine valide notamment la possibilit\u00e9 d\u2019une proc\u00e9dure acc\u00e9l\u00e9r\u00e9e d\u2019autorisation de mise sur le march\u00e9 (Accelerated Approval) et confirme la ... Lire plus","og_url":"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/","og_site_name":"Hemerion","article_published_time":"2026-02-18T09:51:36+00:00","article_modified_time":"2026-02-18T10:00:14+00:00","og_image":[{"width":2000,"height":1328,"url":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/hemerion-treatment.jpg?fit=2000%2C1328&ssl=1","type":"image\/jpeg"}],"author":"Simon Delmotte","twitter_card":"summary_large_image","twitter_creator":"@HemerionTx","twitter_site":"@HemerionTx","twitter_misc":{"\u00c9crit par":"Simon Delmotte","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/#article","isPartOf":{"@id":"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/"},"author":{"name":"Simon Delmotte","@id":"https:\/\/hemerion.com\/fr\/#\/schema\/person\/ec5b45c7f7f52200ee5073ce247a86c7"},"headline":"Retour positif de la FDA sur la strat\u00e9gie clinique de Pentalafen\u00ae \/ Heliance\u00ae dans le traitement du cancer du cerveau, le glioblastome","datePublished":"2026-02-18T09:51:36+00:00","dateModified":"2026-02-18T10:00:14+00:00","mainEntityOfPage":{"@id":"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/"},"wordCount":518,"publisher":{"@id":"https:\/\/hemerion.com\/fr\/#organization"},"image":{"@id":"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/hemerion-treatment.jpg?fit=2000%2C1328&ssl=1","articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/","url":"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/","name":"Retour positif de la FDA sur la strat\u00e9gie clinique de Pentalafen\u00ae \/ Heliance\u00ae dans le traitement du cancer du cerveau, le glioblastome - Hemerion","isPartOf":{"@id":"https:\/\/hemerion.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/#primaryimage"},"image":{"@id":"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/hemerion-treatment.jpg?fit=2000%2C1328&ssl=1","datePublished":"2026-02-18T09:51:36+00:00","dateModified":"2026-02-18T10:00:14+00:00","breadcrumb":{"@id":"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/#primaryimage","url":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/hemerion-treatment.jpg?fit=2000%2C1328&ssl=1","contentUrl":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/hemerion-treatment.jpg?fit=2000%2C1328&ssl=1","width":2000,"height":1328,"caption":"Application de la solution Hemerion au bloc op\u00e9ratoire"},{"@type":"BreadcrumbList","@id":"https:\/\/hemerion.com\/fr\/retour-positif-de-la-fda-sur-la-strategie-clinique-de-pentalafen-heliance-dans-le-traitement-du-cancer-du-cerveau-le-glioblastome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hemerion.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Retour positif de la FDA sur la strat\u00e9gie clinique de Pentalafen\u00ae \/ Heliance\u00ae dans le traitement du cancer du cerveau, le glioblastome"}]},{"@type":"WebSite","@id":"https:\/\/hemerion.com\/fr\/#website","url":"https:\/\/hemerion.com\/fr\/","name":"Hemerion","description":"Advancing cancer therapies at the speed of light","publisher":{"@id":"https:\/\/hemerion.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hemerion.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/hemerion.com\/fr\/#organization","name":"Hemerion","url":"https:\/\/hemerion.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/hemerion.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/hemerion-logo.png?fit=1581%2C460&ssl=1","contentUrl":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/hemerion-logo.png?fit=1581%2C460&ssl=1","width":1581,"height":460,"caption":"Hemerion"},"image":{"@id":"https:\/\/hemerion.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/HemerionTx","https:\/\/www.linkedin.com\/company\/hemerion-therapeutics\/","https:\/\/www.youtube.com\/channel\/UCWwcUj-aSdo32OYwN5vjf8Q"]},{"@type":"Person","@id":"https:\/\/hemerion.com\/fr\/#\/schema\/person\/ec5b45c7f7f52200ee5073ce247a86c7","name":"Simon Delmotte","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/2f742e1ce87613e0ccca0877b0360f87beea918ba8e5efe3717e2c5285bfdc28?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/2f742e1ce87613e0ccca0877b0360f87beea918ba8e5efe3717e2c5285bfdc28?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2f742e1ce87613e0ccca0877b0360f87beea918ba8e5efe3717e2c5285bfdc28?s=96&d=identicon&r=g","caption":"Simon Delmotte"},"url":"https:\/\/hemerion.com\/fr\/author\/simondelmotte\/"}]}},"jetpack_featured_media_url":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/hemerion-treatment.jpg?fit=2000%2C1328&ssl=1","jetpack_shortlink":"https:\/\/wp.me\/pd9WhZ-2r8","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/posts\/9370","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/users\/207845438"}],"replies":[{"embeddable":true,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/comments?post=9370"}],"version-history":[{"count":1,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/posts\/9370\/revisions"}],"predecessor-version":[{"id":9371,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/posts\/9370\/revisions\/9371"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/media\/9369"}],"wp:attachment":[{"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/media?parent=9370"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/categories?post=9370"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/tags?post=9370"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}